Compare
Hepion Pharmaceuticals, Inc. vs Alaunos Therapeutics, Inc. vs Avenue Therapeutics, Inc. vs Neonc Technologies Holdings, Inc.
| Latest fiscal year | Hepion Pharmaceuticals, Inc. HEPA | Alaunos Therapeutics, Inc. TCRT | Avenue Therapeutics, Inc. ATXI | Neonc Technologies Holdings, Inc. NTHI |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $5.0K | $1.40M | $40.0K |
| Revenue growth (YoY) | n/a | -50.0% | n/a | -51.8% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | -219.6% | n/m |
| Net margin | n/a | n/m | -207.2% | n/m |
| Net income | -$8.28M | -$4.18M | -$2.91M | -$62.15M |
| EPS (Diluted) | -$0.88 | -$2.20 | n/a | -$3.20 |
| Operating cash flow | -$3.27M | -$2.87M | -$1.83M | -$20.36M |
| Free cash flow | n/a | -$2.97M | n/a | -$20.86M |
| Cash & equivalents | n/a | $1.39M | $2.85M | $58.7K |
| Total assets | $3.07M | $2.97M | $2.93M | $2.82M |
| Total liabilities | $402.4K | $813.0K | $1.10M | $20.33M |
| Shareholders' equity | $2.67M | $2.15M | $1.83M | -$17.51M |
| Return on year-end equity | -310.3% | -194.0% | -158.8% | n/a |
| Shares outstanding | 11.62M | 2.35M | 3.18M | 21.99M |
Revenue, most recent five fiscal years
| Fiscal year | Hepion Pharmaceuticals, Inc. | Alaunos Therapeutics, Inc. | Avenue Therapeutics, Inc. | Neonc Technologies Holdings, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2023-12-31 | $5.0K Ended 2025-12-31 | $1.40M Ended 2025-12-31 | $40.0K Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2022-12-31 | $10.0K Ended 2024-12-31 | $0 Ended 2024-12-31 | $83.0K Ended 2024-12-31 |
| 2 years earlier | $0 Ended 2021-12-31 | $5.0K Ended 2023-12-31 | n/a | n/a |
| 3 years earlier | $0 Ended 2020-12-31 | $2.92M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | n/a | $398.0K Ended 2021-12-31 | n/a | n/a |